AccessibilityHelpAbout Us
Lixte Biotechnology logo

Lixte Biotechnology(NASDAQ) LIXT

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-91%
5 Year-83%
1 Year-11%
1 Month+7%
N/A
Lixte Biotechnology last closing stock price
MetricPriceDate
Last closeUSD 3.862026-09-08
Lixte Biotechnology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.98%USD 4.102026-09-01
1 month+7.08%USD 3.602026-08-07
3 month-44.05%USD 6.892026-06-10
Year to date-1.91%USD 3.932025-12-31
1 year-10.87%USD 4.332025-09-08
3 year+72.1%USD 2.242023-09-08
5 year-83.24%USD 23.002021-09-09
Since inception-91.43%USD 45.002007-09-21

Lixte Biotechnology Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$8.69M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 14, 2026

LIXT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lixte Biotechnology

NOMAD Power Solutions, Inc. specializes in transportable, utility-grade battery energy storage systems through its subsidiary, NOMAD Transportable Power Systems. The company provides scalable energy solutions for various sectors, including electric utilities and renewable energy integration, while also advancing a life sciences portfolio focused on oncology therapeutics.

Products and Services
  • Transportable battery energy storage systems for utilities
  • Mobile energy solutions for data centers and industrial customers
  • Development of novel oncology therapeutics
Growth Outlook
  • Significant demand for energy storage solutions is expected to rise
  • Expansion into renewable energy markets presents new opportunities
  • Continued investment in oncology therapeutics may enhance market position
Financial Highlights
  • Recent quarterly net income of -$2.19 million reflects ongoing investment
  • Cash and short-term investments increased to $12.67 million in Q2 2026
  • Current ratio of 12.87 indicates strong liquidity position
NOMAD Power Solutions, Inc. is positioned in a growing market, with increasing demand for energy storage solutions driven by the transition to renewable energy. The company's innovative products cater to a diverse range of industries, enhancing its potential for future growth. Recent financial data indicates a robust liquidity position, which may support ongoing investments in product development and market expansion. The focus on oncology therapeutics further diversifies the company's portfolio, potentially leading to additional revenue streams. Overall, NOMAD Power Solutions, Inc. presents an intriguing opportunity for investors interested in the intersection of energy and healthcare sectors.
AI Generated • Sep 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Geordan G. Pursglove

Website

www.nomadpower.com

Headquarters

Boca Raton, FL 33432, US

LIXT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-153.21%

Return on Capital

-49.45%

Return on Assets

-32404.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.96M

EBITDA

-$8.91M

Operating Cash Flow

-$5.46M

Capital Expenditure

$0.00

Free Cash Flow

-$5.46M

Cash & ST Invst.

$12.67M

Total Debt

$1.10M

Lixte Biotechnology Performance Analysis

Lixte Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lixte Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Lixte Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.99-20.1%
20232023-12-31USD -2.66-33.5%
20242024-12-31USD -1.59-40.0%
20252025-12-31USD -1.26-21.2%
Lixte Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-13.8%
Q42025-12-31N/A
Q12026-03-3145.5%
Q22026-06-3011.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

3

N/A

Net Income

-$2.19M

-182.0%

EBITDA

-$2.35M

-203.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$12.67M

+1328.1%

Total Debt

$1.10M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$161.02K

N/A

Short Term Debt

$940.78K

N/A

Return on Assets

-324.05%

N/A

Return on Invested Capital

-316.65%

N/A

Free Cash Flow

-$1.59M

-225.6%

Operating Cash Flow

-$1.61M

-230.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALLRAllarity Therapeutics, Inc.
$1.25+0.00%
CINGCingulate Inc.
$5.34+2.89%
BCTXBriaCell Therapeutics Corp.
$3.59+0.42%
PULMPulmatrix, Inc.
$1.56+11.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.73-0.04%
NOKNokia
$10.91+0.02%
INTCIntel
$105.46+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.57+0.00%

Questions About LIXT

What is the current price of Lixte Biotechnology?

Lixte Biotechnology is trading at N/A per share.

What is the 52-week range for Lixte Biotechnology?

Over the past 52 weeks, Lixte Biotechnology has traded between N/A and N/A.

How much debt does Lixte Biotechnology have?

As of the most recent reporting period, Lixte Biotechnology reported total debt of $1.10M.

How much cash does Lixte Biotechnology have on hand?

Lixte Biotechnology reported $12.67M in cash and cash equivalents in its most recent financial results.

What is Lixte Biotechnology’s dividend yield?

Lixte Biotechnology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services